)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals (ACAD) investor relations material
ACADIA Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Q3 GAAP revenue was $342.3M, up 23% YoY; adjusted-basis growth was 22%, with DAYBUE and NUPLAZID sales growth.
Operating income rose to $71.7M from $35.8M; net income declined to $53.5M from $71.8M amid a less favorable tax comparison.
DAYBUE guidance increased, while RADIANT results informed a 60 mg-focused phase III plan for remlifanserin.
Financial highlights
Q3 revenue was $342.3M vs. $278.6M GAAP in Q3 2025; compared with adjusted prior-year revenue of $280.9M, growth was 22%.
DAYBUE net sales were $140.1M vs. $101.1M; NUPLAZID net sales were $202.2M vs. $179.8M adjusted, or $177.5M GAAP.
R&D expense was $76.3M vs. $87.8M; SG&A was $159.2M vs. $133.4M, reflecting commercial investment and lower spending on completed studies.
Q3 diluted EPS was $0.31 vs. $0.42; income tax expense was $26.9M vs. a $27.2M tax benefit in Q3 2025.
Outlook and guidance
FY26 total revenue guidance is $1.265B–$1.295B; DAYBUE global net sales guidance rose to $505M–$520M from $480M–$510M.
FY26 NUPLAZID net sales guidance is $760M–$775M; gross-to-net guidance is 23%–24% for DAYBUE and 22%–23% for NUPLAZID.
FY26 R&D expense guidance is $325M–$340M, reduced from $355M–$380M; SG&A guidance is $665M–$685M.
Phase 2 readouts are expected in 2H 2027 for ACP-211 in MDD and Q4 2027 for remlifanserin in LBDP; ACP-711 essential tremor Phase 2 is expected to begin in 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ACADIA Pharmaceuticals
- Priority review and launch preparations advanced as 2015 net loss reached $164.4M.ACAD
Q4 2015 - NUPLAZID launched; $529.0 million in cash supported an expanded CNS pipeline.ACADQ4 2016
- NUPLAZID sales surged, but rising launch and pipeline costs drove a $289.4 million net loss.ACADQ4 2017
- NUPLAZID growth funded a broader pipeline, but losses and commercialization risks remained.ACADQ4 2018
- NUPLAZID grew 52%, while pivotal pipeline progress met ongoing execution and funding risks.ACADQ4 2019
- NUPLAZID sales grew 30%, while losses widened and DRP approval faced an FDA setback.ACADQ4 2020
- NUPLAZID growth and positive Rett results advanced the pipeline amid pandemic and regulatory risks.ACADQ4 2021
- Higher R&D widened losses as sales grew; DAYBUE approval opened a second growth front.ACADQ4 2022
- FY23 revenue rose 40% to $726.4M as DAYBUE launched and net loss narrowed.ACADQ4 2023
Next ACADIA Pharmaceuticals earnings date
UBS Global Biopharma Conference 202617 Nov, 2026
ACADIA Pharmaceuticals
Next ACADIA Pharmaceuticals earnings date
UBS Global Biopharma Conference 202617 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ACADIA Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of therapies addressing central nervous system disorders. The company offers treatments for conditions such as Parkinson’s disease psychosis and other neurological diseases. ACADIA operates within the healthcare sector, concentrating on innovative solutions for underserved medical needs. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.